TLR9 anticorps (AA 100-290) (FITC)

N° du produit ABIN5564254

Détail du produit anti-TLR9 anticorps (FITC)

Antigène: TLR9 (Toll-Like Receptor 9 (TLR9))

Épitope: AA 100-290

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TLR9 est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Specificité: Recognizes human and mouse TLR9.

Réactivité croisée: Humain, Souris

Purification: Protein G purified.

Immunogène: Recombinant human TLR9 protein (aa 100-290).

Clone: ABM1C51

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: In 10 mM TRIS containing 150 mM NaCl and 0.05 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Short Term Storage: +4°C
Long Term Storage: +4°C
Stable for at least 6 months after receipt when stored at +4°C.

Date de péremption: 6 months

Détails sur TLR9

Antigène: TLR9 (Toll-Like Receptor 9 (TLR9))

Autre désignation: TLR9 (TLR9 Produits)

Synonymes: anticorps CD289, anticorps toll like receptor 9, anticorps toll-like receptor 9, anticorps TLR9, anticorps Tlr9

Sujet: TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.

Pathways: Signalisation TLR, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades